Details for Patent: 7,978,064

Which drugs does patent 7,978,064 protect, and when does it expire?

Patent 7,978,064 protects ABILIFY MYCITE KIT and is included in one NDA.

This patent has one hundred and twenty-five patent family members in twenty-two countries.

Summary for Patent: 7,978,064

Title:	Communication system with partial power source
Abstract:	The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can be used in a variety of different applications, including as components of ingestible identifiers, such as may be found in ingestible event markers, e.g., pharma-informatics enabled pharmaceutical compositions.
Inventor(s):	Zdeblick; Mark (Portola Valley, CA), Robertson; Timothy (Belmont, CA), Pikelny; Aleksandr (Los Angeles, CA), Hafezi; Hooman (Redwood City, CA)
Assignee:	Proteus Biomedical, Inc. (Redwood City, CA)
Application Number:	12/564,017
Patent Claim Types: see list of patent claims	Use; Process; Device;

Drugs Protected by US Patent 7,978,064

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-001	Nov 13, 2017		RX	Yes	No			Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		RX	Yes	Yes			Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		RX	Yes	No			Y

International Family Members for US Patent 7,978,064

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006239221
Australia	2012282690
Australia	2012282772